The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.
Hair loss treatment progress after 8 months using finasteride, minoxidil, nizoral, and dermarolling. Discussion includes positive feedback on results and question about needle replacement for dermarolling.
Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.
Epibiotech will offer off-the-shelf allogeneic hair multiplication treatment in South Korea, using dermal papilla cells from donors to grow hair in balding areas. This method is cheaper and less invasive than traditional hair transplants.
GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.
Topical 2-deoxy-D-ribose (2dDR) regrows hair in mice almost as well as 2% Minoxidil. However, 2dDR may contribute to oxidative stress and hair loss due to the formation of advanced glycation end products (AGEs).
The conversation is about the release of Phase 3 trial results for pyrilutamide in China for treating hair loss. The user is inquiring if the actual results have been posted, noting that a recent release did not contain them.
Verteporfin shows promise in donor hair regeneration after 84 days. Combining Finasteride, Minoxidil, and Pyrilutamide with unlimited hair transplants is seen as a potential near-cure for hair loss.
A user's two month update on their hair loss journey and the treatments they are trying, which include exosome injections, minoxidil, finasteride, and RU58841.
Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.
The user successfully maintained and regrew hair using finasteride for 11 years and oral minoxidil for 9 months, experiencing no significant side effects. They plan to continue these treatments to prevent hair loss.
The user has been using a spray containing minoxidil and finasteride for 19 months and started oral finasteride 9 months ago. They plan to begin dermarolling.
A user shared successful hair regrowth results after 9 months using 0.5mg Dutasteride and 2.5mg Minoxidil daily, with no side effects. The user chose Dutasteride over Finasteride for its potency and perceived lower side effects.
The user is taking 1mg Dutasteride, 2.5mg oral Minoxidil, topical Minoxidil, 28mg iron, vitamin D3 + K2, and Selenium daily. They are concerned about their receding hairline despite good hair density and crown.
Finasteride and Dutasteride used in combination with RU58841 and microneedling, as a treatment for hair loss. There was discussion on progress of the treatment and potential other methods to consider.
The conversation is about the availability of the research chemical GT20029 for hair loss treatment and when companies like Anageninc will have it. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.
CosmeRNA, a new hair loss treatment, is expected to release soon and may become part of the "big three" treatments alongside finasteride and minoxidil. It works differently from finasteride by targeting androgen receptors in hair follicles, potentially offering fewer side effects.
A user shared their 10-month hair loss progress using Propecia, oral minoxidil, and topical minoxidil. The results were highly praised, with requests for more details on dosages and routine.
A user diagnosed with lymphoma is advised to stop finasteride during chemotherapy, with suggestions to consider treatments like Dutasteride and Minoxidil post-recovery. The focus is on prioritizing health over hair loss, with encouragement and advice from others who have experienced similar situations.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
A 19-year-old male shared progress pictures showing hair regrowth on his scalp after starting a treatment with Minoxidil and Finasteride on November 24th. He noted improved hair texture and a halt in hair shedding for the past two weeks.
The user has been using Minoxidil and finasteride with success and is now trying Dualgen-5R with retinoic acid but without finasteride, along with microneedling. They plan to share results in 5-6 months.
The user's 42 month experience using finasteride for hair loss, their opinion on minoxidil use and the potential of pyrilutamide and another Chinese drug as treatments.
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
The conversation discusses hair loss treatments, focusing on vitamin D and B12 deficiencies, and mentions using finasteride. It also suggests getting a biopsy to differentiate between MPB and other conditions.